Authors
Dario de Biase, Thais Maloberti, Giulia Ciccimarra, Laura Poppi, Giulia Calafato, Deborah Malvi, Michele Carroli, Luca Saragoni, Giovanni Tallini, Francesco Vasuri
Published in
Pathologica. Volume 118. Issue 3. Pages 181-186.
Abstract
Cholangiocarcinoma (CCA) is an aggressive malignancy with limited therapeutic options and poor prognosis. Advances in next-generation sequencing (NGS) revealed distinct molecular profiles between intrahepatic (iCCA) and extrahepatic (eCCA) subtypes, identifying recurrent mutations with diagnostic and therapeutic significance. We evaluated the performance of a laboratory-developed NGS panel designed for the integrated diagnostic and predictive profiling of CCA.
In this multicentric retrospective study, 50 biopsies were analyzed, achieving 92% success rate. Pathogenic variants were identified in 58.7% of samples, with TP53 (26.1%) and KRAS (21.7%) as the most frequently mutated genes. Multiple mutations were observed in 14 cases, the most frequent co-mutation being KRAS plus TP53 (6 cases). Non-druggable but diagnostically relevant genes (e.g., ARID1A, BAP1) were added to enhance classification accuracy.
Despite limitations such as the inability to detect gene fusions (e.g., FGFR2), the panel demonstrated strong analytical feasibility and clinical utility. Integrating DNA/RNA sequencing, optimized pre-analytical workflows, and multidisciplinary interpretation will refine precision oncology approaches for CCA management in the future.
PMID:
43012438
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0